Home > News > Aptamers

Fully Optimised Aptamers

Introducing OptimersTM
3rd October 2018
 
Proprietary process with validated improvement in delivery and performance

OptimersTM in 12 weeks
Aptamer Group is pleased to announce availability of  OptimersTM – the new standard for our custom development services.

Aptamer Group is dedicated to continually improve its service offerings to identify the best reagent(s) from within our vast aptamer libraries in the […]

Aptamer Stability

29th August 2018
At Aptamer Group, every custom aptamer project begins with a feasibility study. The target and assay matrix are tested for compatibility and stability with the aptamer library, under a variety of conditions. At this early stage it is important to understand the optimal strategy for the selection, address any potential issues and […]

Portable Aptamer Based Sensor for Toxin Detection

9th August 2018 
Aptamers continue to demonstrate advantages in platforms and applications which require specific detection of small molecule targets.
There has been a growth in the use of point of care devices across a range of applications and assay types due to a need for rapid and reliable analysis (Vashist 2017). Aptamers are perfectly suited for […]

Aptamer-based Lab on chip for the rapid detection of food-borne pathogens

1st August 2018
Scientists from the Technical University of Denmark, led by  Krishna  Kant have published a new review in Biotechnology Advances including  aptamer-based approaches  for the rapid detection of food-borne pathogens.
Food borne diseases, caused by the consumption of foods contaminated with pathogens or their toxins, are one of the major burdens to public health, causing […]

Aptamer Group Secures $2.2m Series A Investment

Arron Tolley, CEO – I’m delighted to announce that Aptamer Group Ltd, has recently closed its Series A investment round; attracting international interest and securing $2.2m of funding from overseas investors, to support its pioneering aptamer development pipeline.

Aptamer technology is rapidly evolving and will continue to have a significant impact on the life sciences market […]

Congratulations to Dr Mateja Vidic

1st June 2018

We are very pleased to announce that Mateja Vidic has completed and been awarded her PhD for the Development of DNA Aptamers Specific for Non-Small Cell Lung Cancer by the University of Ljubljana, Slovenija. Her experience in aptamer selection and application is a valuable asset to our lab and we are very proud […]

New licenses for Aptamer Group aptamers for innovative diagnostic development

Exclusive licence deals to follow successful custom aptamer selection
25th May 2018
Aptamer Group is pleased to announce that we are now working on multiple projects where long term licencing deals have been negotiated with customers based in the UK and USA. This is an important ongoing commercial strategy for us and we look forward to developing […]

Aptamers excel as binding reagents in ELISA replacement assays for antibiotics in complex media such as plasma, milk and others

18th May 2018.

Traditionally small molecules, such as antibiotics, have been difficult targets for ELISA development. Aptamer Group has selected aptamers that bind to small molecules, previously inaccessible to other binding technologies. Utilising our state-of-the-art automation and parallel processing techniques, we can select high affinity and highly specific aptamers against small molecule targets, in solution. These […]

Biosensors developed using aptamers distinguish between closely related small molecules

4th May 2018

Development of biosensors for the detection of small molecules is notoriously difficult due to the lack of suitable antibodies and the relatively small signals, which result upon small molecule binding to them. At Aptamer Group we select aptamers that bind to small molecules with high specificity and undergo a substantial conformational change that gives […]

Cell Imaging – Aptamers can monitor the different stages of cancer

18th April 2018
Previously we introduced aptamers as a tool for cell specific staining. Here we have taken this technology a step further to demonstrate that aptamers can monitor disease progression in cancer.

By utilising our selection methodology, we can rapidly isolate aptamers against cells in different disease states. Through this process we have been able to identify […]